Clone Number: ZR8
Immunogen: Synthesized polypeptides from N-terminal domain of p63
Concentration: n/a
Format: Purified
Storage buffer: Purified antibody in 0.2% BSA and 15mM sodium azide.
Additional info: p63 consists of two major isoforms -TAp63 and ΔNp63. These isoforms differ in the structure of the N-terminal domains. The TAp63 isoform (identified by anti-p63 antibody) contains a transactivation- competent ‘TA’domain with homology to p53, which regulates the expression of the growth -inhibitor y genes. In contrast, ΔNp63 isoform (identified by anti-p40 antibody) contains an alternative transcriptionally- inactive ‘ΔN’ domain, which antagonizes the activity of TAp63 and p53. The p40 (clone ZR8) recognizes exclusively ΔNp63 but not TAp63. p40 is a squamous cell carcinoma ‘specific’ antibody. It reacts with the vast majority of cases of squamous cell carcinomas of various origins, but not with adenocarcinomas. It is particularly useful in differentiating lung squamous cell carcinoma from lung adenocarcinoma. p40 antibody can also be used as an alternative basal cell/myoepithelial cell marker, which has similar sensitivity and specificity as that of p63 antibody. Therefore, p40 antibody may also be used as an alternative immunohistochemical marker for determining prostate adenocarcinoma vs. benign prostate glands and for determining breast intraductal carcinoma v s. invasive breast ductal carcinoma. Pretreatment: Heat induced epitope retrieval in 10 mM citrate buffer, pH6.0, or in 50 mM Tris buffer pH9.5, for 20 minutes is required for IHC staining on formalin-fixed, paraffin embedded tissue sections. Note: Dilution of the antibody in 10% normal goat serum followed by a goat anti-rabbit secondary antibody-based detection is recommended. Control tissue Lung squamous cell carcinoma. Staning nuclear
English
Deutsch
